The transcription factor BACH2 promotes tumor immunosuppression

Rahul Roychoudhuri, Robert L. Eil, David Clever, Christopher A. Klebanoff, Madhusudhanan Sukumar, Francis M. Grant, Zhiya Yu, Gautam Mehta, Hui Liu, Ping Jin, Yun Ji, Douglas C. Palmer, Jenny H. Pan, Anna Chichura, Joseph G. Crompton, Shashank J. Patel, David Stroncek, Ena Wang, Francesco M. Marincola, Klaus OkkenhaugLuca Gattinoni, Nicholas P. Restifo

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4+ and CD8+ T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3+ Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.

Original languageEnglish
Pages (from-to)599-604
Number of pages6
JournalJournal of Clinical Investigation
Volume126
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Fingerprint

Immunosuppression
Transcription Factors
Neoplasms
T-Lymphocytes
Immune System
Tumor-Infiltrating Lymphocytes
Adaptive Immunity
Innate Immunity
Immunity
Cytokines
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roychoudhuri, R., Eil, R. L., Clever, D., Klebanoff, C. A., Sukumar, M., Grant, F. M., ... Restifo, N. P. (2016). The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 126(2), 599-604. https://doi.org/10.1172/JCI82884

The transcription factor BACH2 promotes tumor immunosuppression. / Roychoudhuri, Rahul; Eil, Robert L.; Clever, David; Klebanoff, Christopher A.; Sukumar, Madhusudhanan; Grant, Francis M.; Yu, Zhiya; Mehta, Gautam; Liu, Hui; Jin, Ping; Ji, Yun; Palmer, Douglas C.; Pan, Jenny H.; Chichura, Anna; Crompton, Joseph G.; Patel, Shashank J.; Stroncek, David; Wang, Ena; Marincola, Francesco M.; Okkenhaug, Klaus; Gattinoni, Luca; Restifo, Nicholas P.

In: Journal of Clinical Investigation, Vol. 126, No. 2, 01.02.2016, p. 599-604.

Research output: Contribution to journalReview article

Roychoudhuri, R, Eil, RL, Clever, D, Klebanoff, CA, Sukumar, M, Grant, FM, Yu, Z, Mehta, G, Liu, H, Jin, P, Ji, Y, Palmer, DC, Pan, JH, Chichura, A, Crompton, JG, Patel, SJ, Stroncek, D, Wang, E, Marincola, FM, Okkenhaug, K, Gattinoni, L & Restifo, NP 2016, 'The transcription factor BACH2 promotes tumor immunosuppression', Journal of Clinical Investigation, vol. 126, no. 2, pp. 599-604. https://doi.org/10.1172/JCI82884
Roychoudhuri R, Eil RL, Clever D, Klebanoff CA, Sukumar M, Grant FM et al. The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation. 2016 Feb 1;126(2):599-604. https://doi.org/10.1172/JCI82884
Roychoudhuri, Rahul ; Eil, Robert L. ; Clever, David ; Klebanoff, Christopher A. ; Sukumar, Madhusudhanan ; Grant, Francis M. ; Yu, Zhiya ; Mehta, Gautam ; Liu, Hui ; Jin, Ping ; Ji, Yun ; Palmer, Douglas C. ; Pan, Jenny H. ; Chichura, Anna ; Crompton, Joseph G. ; Patel, Shashank J. ; Stroncek, David ; Wang, Ena ; Marincola, Francesco M. ; Okkenhaug, Klaus ; Gattinoni, Luca ; Restifo, Nicholas P. / The transcription factor BACH2 promotes tumor immunosuppression. In: Journal of Clinical Investigation. 2016 ; Vol. 126, No. 2. pp. 599-604.
@article{d923913ed58142218f3c12da07a9e956,
title = "The transcription factor BACH2 promotes tumor immunosuppression",
abstract = "The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4+ and CD8+ T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3+ Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.",
author = "Rahul Roychoudhuri and Eil, {Robert L.} and David Clever and Klebanoff, {Christopher A.} and Madhusudhanan Sukumar and Grant, {Francis M.} and Zhiya Yu and Gautam Mehta and Hui Liu and Ping Jin and Yun Ji and Palmer, {Douglas C.} and Pan, {Jenny H.} and Anna Chichura and Crompton, {Joseph G.} and Patel, {Shashank J.} and David Stroncek and Ena Wang and Marincola, {Francesco M.} and Klaus Okkenhaug and Luca Gattinoni and Restifo, {Nicholas P.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1172/JCI82884",
language = "English",
volume = "126",
pages = "599--604",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - The transcription factor BACH2 promotes tumor immunosuppression

AU - Roychoudhuri, Rahul

AU - Eil, Robert L.

AU - Clever, David

AU - Klebanoff, Christopher A.

AU - Sukumar, Madhusudhanan

AU - Grant, Francis M.

AU - Yu, Zhiya

AU - Mehta, Gautam

AU - Liu, Hui

AU - Jin, Ping

AU - Ji, Yun

AU - Palmer, Douglas C.

AU - Pan, Jenny H.

AU - Chichura, Anna

AU - Crompton, Joseph G.

AU - Patel, Shashank J.

AU - Stroncek, David

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Okkenhaug, Klaus

AU - Gattinoni, Luca

AU - Restifo, Nicholas P.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4+ and CD8+ T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3+ Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.

AB - The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4+ and CD8+ T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3+ Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.

UR - http://www.scopus.com/inward/record.url?scp=84956901724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956901724&partnerID=8YFLogxK

U2 - 10.1172/JCI82884

DO - 10.1172/JCI82884

M3 - Review article

C2 - 26731475

AN - SCOPUS:84956901724

VL - 126

SP - 599

EP - 604

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -